Skip to main content

The AHRQ National Quality Measures Clearinghouse (NQMC, qualitymeasures.ahrq.gov) Web site will not be available after July 16, 2018 because federal funding
through AHRQ will no longer be available to support the NQMC as of that date. For additional information, read our full announcement.
  • Measure Summary
  • NQMC:010885
  • Dec 2009

AIDS Drug Assistance Program (ADAP): percentage of ADAP enrollees who are reviewed for continued ADAP eligibility two or more times in the measurement year.

Health Resources and Services Administration (HRSA). HAB HIV performance measures. ADAP: AIDS Drug Assistance Program. Rockville (MD): Health Resources and Services Administration (HRSA); 2009 Dec 10. 9 p.

View the original measure documentation External Web Site Policy

This is the current release of the measure.

Primary Measure Domain

Population Health Quality Measures: Population Process

Secondary Measure Domain

Does not apply to this measure

Description

This measure is used to assess the percentage of AIDS Drug Assistance Program (ADAP) enrollees who are reviewed for continued ADAP eligibility two or more times in the measurement year.

Rationale

Human immunodeficiency virus (HIV)-related morbidity and mortality has dropped dramatically due to advances in HIV/acquired immune deficiency syndrome (AIDS) treatment. But reductions are uneven across HIV-infected populations due to unequal access to care and variable quality of services provided. Quality management seeks to enhance the quality of HIV care provided and increase access to services. They do so by measuring how health and social services meet established professional standards and user expectations.

The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415) requires that the Ryan White HIV/AIDS Program be the payor of last resort. HIV/AIDS Bureau (HAB) Policy 07-03 specifies that "grantees must be capable of providing the HAB with documentation related to the use of funds as payor of last resort and the coordination of such funds with other local, state and federal funds" (Hopson, 2007).

U.S. Public Health Service Guidelines

This measure addresses the intent of U.S. Department of Health and Human Services (HHS) treatment guidelines for the use of antiretroviral agents and the prevention and treatment of opportunistic infections in HIV infected individuals (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009; Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, 2009; Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, 2009; Kaplan et al., 2009; Mofenson et al., 2009).

Evidence for Rationale

Health Resources and Services Administration (HRSA). Deliver HIV/AIDS care: quality of care. [internet]. Rockville (MD): Health Resources and Services Administration (HRSA); [accessed 2016 Jun 23].

Health Resources and Services Administration (HRSA). HAB HIV performance measures. ADAP: AIDS Drug Assistance Program. Rockville (MD): Health Resources and Services Administration (HRSA); 2009 Dec 10. 9 p.

Hopson DP. Policy notice-07-03: the use of Ryan White HIV/AIDS Program, Part B (formerly Title II), AIDS Drug Assistance Program (ADAP) funds for access, adherence and monitoring services. Rockville (MD): Health Resources and Services Administration (HRSA); 2007 Sep. 4 p.

Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4. PubMed External Web Site Policy

Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read JS, Serchuck L, Van Dyke R, Centers for Disease Control and Prevention, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association [trunc]. MMWR Recomm Rep. 2009 Sep 4;58(RR-11):1-166.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda (MD): Department of Health and Human Services (DHHS); 2009 Dec 1. 161 p.

Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Bethesda (MD): Department of Health and Human Services (DHHS); 2009 Apr 29. various p.

The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415), Section 202(a).

Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): Department of Health and Human Services (DHHS); 2009 Feb 23. various p.

Primary Health Components

Human immunodeficiency virus (HIV); AIDS Drug Assistance Program (ADAP); enrollment eligibility; recertification

Denominator Description

Number of clients enrolled in the AIDS Drug Assistance Program (ADAP) in the measurement year (see the related "Denominator Inclusions/Exclusions" field)

Numerator Description

Number of AIDS Drug Assistance Program (ADAP) enrollees who are reviewed for continued ADAP eligibility at least two or more times which are at least 150 days apart in the measurement year (see the related "Numerator Inclusions/Exclusions" field)

Type of Evidence Supporting the Criterion of Quality for the Measure

  • A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

Additional Information Supporting Need for the Measure

Unspecified

Extent of Measure Testing

Unspecified

State of Use

Current routine use

Current Use

External oversight/State government program

Internal quality improvement

Population health improvement

Measurement Setting

State/Provincial Public Health Programs

Professionals Involved in Delivery of Health Services

Public Health Professionals

Least Aggregated Level of Services Delivery Addressed

State/Provincial

Statement of Acceptable Minimum Sample Size

Does not apply to this measure

Target Population Age

All individuals, regardless of age

Target Population Gender

Either male or female

Public Health Aims for Quality

Effective

Population-centered

Proactive

National Quality Strategy Aim

Healthy People/Healthy Communities

National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

IOM Care Need

Living with Illness

IOM Domain

Effectiveness

Case Finding Period

The measurement year

Denominator Sampling Frame

Enrollees or beneficiaries

Denominator (Index) Event or Characteristic

Patient/Individual (Consumer) Characteristic

Denominator Time Window

Does not apply to this measure

Denominator Inclusions/Exclusions

Inclusions
Number of clients enrolled* in the AIDS Drug Assistance Program (ADAP)** in the measurement year

Note: Refer to the original measure documentation for additional data elements.

*Includes all individuals, regardless of age.

**Clients Enrolled in ADAP: Refers to "the total number of individuals who are enrolled or certified as eligible to receive medications in…ADAP, regardless of whether they used ADAP services."

Exclusions

  • Clients approved for new ADAP enrollment in the measurement year.
  • Clients terminated from ADAP in the first 180 days of the measurement year.

Exclusions/Exceptions

Does not apply to this measure

Numerator Inclusions/Exclusions

Inclusions
Number of AIDS Drug Assistance Program (ADAP) enrollees who are reviewed for continued ADAP eligibility* at least two or more times which are at least 150 days apart in the measurement year

*Review for Continued ADAP Enrollment (recertification) is a process for "confirming that a client receiving ADAP-funded services is still eligible to receive those services." Verification of ADAP eligibility includes verification of third party payor sources, such as Medicaid and Medicare.

Exclusions
Unspecified

Numerator Search Strategy

Fixed time period or point in time

Data Source

National public health data

State/Province public health data

Type of Health State

Does not apply to this measure

Instruments Used and/or Associated with the Measure

Unspecified

Measure Specifies Disaggregation

Does not apply to this measure

Scoring

Rate/Proportion

Interpretation of Score

Desired value is a higher score

Allowance for Patient or Population Factors

Unspecified

Standard of Comparison

Internal time comparison

Prescriptive standard

Prescriptive Standard

National Goals, Targets, or Benchmarks for Comparison:

  • Part B Collaborative*: 92%

*Part B Collaborative measure reads "percent of ADAP enrollees recertified for ADAP eligibility criteria at least annually."

Evidence for Prescriptive Standard

Health Resources and Services Administration (HRSA). HAB HIV performance measures. ADAP: AIDS Drug Assistance Program. Rockville (MD): Health Resources and Services Administration (HRSA); 2009 Dec 10. 9 p.

Original Title

ADAP: eligibility recertification.

Measure Collection Name

HIV/AIDS Bureau (HAB) Performance Measures

Measure Set Name

AIDS Drug Assistance Program

Submitter

Health Resources and Services Administration - Federal Government Agency [U.S.]

Developer

Health Resources and Services Administration - Federal Government Agency [U.S.]

Funding Source(s)

Unspecified

Composition of the Group that Developed the Measure

Unspecified

Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2009 Dec

Measure Maintenance

Unspecified

Date of Next Anticipated Revision

Unspecified

Measure Status

This is the current release of the measure.

Source(s)

Health Resources and Services Administration (HRSA). HAB HIV performance measures. ADAP: AIDS Drug Assistance Program. Rockville (MD): Health Resources and Services Administration (HRSA); 2009 Dec 10. 9 p.

Measure Availability

Source available from the Health Resources and Services Administration (HRSA) Web site External Web Site Policy.

For more information, contact the HRSA HIV/AIDS Bureau (HAB) at 5600 Fishers Lane, Rockville, MD 20857; E-mail: HIVmeasures@hrsa.gov; Web site: www.hrsa.gov/index.html External Web Site Policy.

NQMC Status

This NQMC summary was completed by ECRI Institute on July 8, 2016.

Copyright Statement

No copyright restrictions apply.

NQMC Disclaimer

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.